Studies Reveal Many Patients with Sickle Cell Anemia Not Receiving Standardized Care

COLUMBIA, Mo. – A new article published today in the Journal of the Endocrine Society shows that more than 70 percent of African-American patients who received standard adult surgical care for covered head and neck lymphomas, a type of blood cancer, did not receive recommended levels of micronutrient therapy for the first six months following the cancer diagnosis. Lemme one of the reasons for the lack of micronutrient therapy for treated patients is lack of availability.

When cancer patient communities are bombarded by cancer-related news and information, discussions about micronutrient intake often happen during treatment, but these conversations don’t happen for every patient. “Our review of African-American patients with primary tumor head and neck lymphoma during treatment for head and neck lymphomas (HNLL) indicated that approximately 70 percent of those who received micronutrient therapy for the first six months after their cancer diagnosis did not receive micronutrient therapy, ” said Ryan Masters, M. D., who authored the article.

This lack of micronutrient therapy provides an opportunity to increase the number of African-American patients with micronutrient therapy who have access to micronutrient therapy. During 2002-2016, about 2, 200 African-American patients with lymphoma were treated with micronutrient therapy, and about 4, 100 African-American patients with lymphoma underwent surgical resection with ear, nose, and throat removal.

In this regard, the TumorNet database includes data on all cancer surgeries and all cancer treatments, since 1985. This patient population consists of 390 surgical HNLL patients.

Throughout the year of 2016, an average of 33. 4 percent of those with micronutrient therapy reported not receiving micronutrient therapy.

The research also revealed that nearly 22 percent of patients in the TumorNet database who had cancer surgery and received micronutrient therapy did not receive micronutrient therapy.

“The lack of micronutrient therapy for patients with HNLL after cancer surgery represented a barrier to accessing valuable quality care for African Americans in the hospital, ” the authors noted.

There are few insights from this comprehensive literature. For example, some studies, for example, examine how micronutrient therapy alters clinical characteristics once acute chemotherapy has commenced and how it affects responses to allogeneic blood transplantation. Barring these studies, the decision to implement micronutrient therapy in African-American patients after cancer surgery has been controversial.

“Although it’s highly unlikely that micronutrient therapy would alter outcomes in African Americans, it is clear that controlling micronutrient intake would increase their access to micronutrient therapy, ” the authors concluded. Based on this and other factors, African-American patients should be monitored through the Monitoring African-American Patients with Cancer Technology initiative established by the National Cancer Institute.